New drug aims to tame severe allergies by targeting IgE
NCT ID NCT07408869
First seen Feb 19, 2026 · Last updated May 05, 2026 · Updated 9 times
Summary
This early-stage study tests a new medicine called cizutamig in 20 adults with severe allergies, including food allergies. The goal is to see if it safely lowers IgE, a key antibody involved in allergic reactions. Participants will receive the drug and be monitored for side effects and changes in their allergy markers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGE-MEDIATED COW MILK ALLERGY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nucleus Network
Melbourne, Victoria, 3004, Australia
Contact
Conditions
Explore the condition pages connected to this study.